Verinnogen Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $677K

  • Investors
  • 7

Verinnogen General Information

Description

Developer of a hand-held device designed to profile three-dimensional surfaces for pre-clinical cancer research. The company offers tools that improve accuracy and reduce operator error, enabling researchers to achieve more efficient translation of cancer therapies for clinical evaluation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 9 Quy Court
  • Cambridge CB25 9AU
  • England, United Kingdom
+44 07920
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Devices and Supplies
Vertical(s)
Corporate Office
  • Unit 9 Quy Court
  • Cambridge CB25 9AU
  • England, United Kingdom
+44 07920

Verinnogen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verinnogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 11-May-2026 $677K Completed Pre-Clinical Trials
3. Later Stage VC 30-Mar-2026 Completed Pre-Clinical Trials
2. Later Stage VC 22-Dec-2025 $1.13M $1.65M Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Feb-2023 $520K $520K Completed Pre-Clinical Trials
To view Verinnogen’s complete valuation and funding history, request access »

Verinnogen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary A
Ordinary A
Ordinary A 469,741 $0.000133 $1.2 $1.2 1x $1.2 21.54%
To view Verinnogen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Verinnogen Patents

Verinnogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4412519-A1 Surface profiler Active 08-Oct-2021
EP-4412519-B1 Surface profiler Active 08-Oct-2021
EP-4412519-C0 Surface profiler Active 08-Oct-2021
ES-3064067-T3 Surface profiler Active 08-Oct-2021
GB-202114406-D0 Surface profiler Pending 08-Oct-2021 A61B5/1072
To view Verinnogen’s complete patent history, request access »

Verinnogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verinnogen Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Centre for Process Innovation Corporate Venture Capital Minority
EverQuest Capital Partners PE/Buyout Minority
Cambridge Angels Angel Group Minority
Cambridge Enterprise Ventures Venture Capital Minority
Cancer Research Technology Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Verinnogen FAQs

  • When was Verinnogen founded?

    Verinnogen was founded in 2019.

  • Where is Verinnogen headquartered?

    Verinnogen is headquartered in Cambridge, United Kingdom.

  • What is the size of Verinnogen?

    Verinnogen has 8 total employees.

  • What industry is Verinnogen in?

    Verinnogen’s primary industry is Discovery Tools (Healthcare).

  • Is Verinnogen a private or public company?

    Verinnogen is a Private company.

  • What is Verinnogen’s current revenue?

    The current revenue for Verinnogen is .

  • How much funding has Verinnogen raised over time?

    Verinnogen has raised $3M.

  • Who are Verinnogen’s investors?

    Centre for Process Innovation, EverQuest Capital Partners, Cambridge Angels, Cambridge Enterprise Ventures, and Cancer Research Technology are 5 of 7 investors who have invested in Verinnogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process